Anke Bio: Verification opinions of the Remuneration and Assessment Committee of the 8th Board of Directors on matters related to the company’s third phase of restricted stock incentive plan
Anhui Anke Bioengineering (Group) Co., Ltd.
Verification Opinions of the Remuneration and Assessment Committee of the Eighth Board of Directors on Matters Related to the Company’s Third Restricted Stock Incentive Plan
The Remuneration and Appraisal Committee of the 8th Board of Directors of Anhui Anke Bioengineering (Group) Co., Ltd. (hereinafter referred to as the "Company") is based on the Company Law, the Measures for the Administration of Equity Incentives for Listed Companies, the Articles of Association, the Working Rules of the Remuneration and Appraisal Committee of the Board of Directors, and the Implementation Assessment Management Office of the Company's Third Phase Restricted Stock Incentive Plan. Law (Revised Draft)" and other relevant regulations, the Company reviewed the achievements of the initial grant part and the reserved grant part of the company's third phase of the restricted stock incentive plan in terms of the lifting of restrictions on sales, as well as the repurchase and cancellation of shares of resignation incentive objects, and verified the list of incentive objects and the number to be unlocked during the lifting of the restriction period, and issued the following opinions:
The company's implementation of the unlocking of restricted stocks this time complies with relevant regulations such as the "Measures for the Administration of Equity Incentives for Listed Companies", the "Company's Third Phase Restricted Stock Incentive Plan (Draft Revised)" and the "Company's Third Phase Restricted Stock Incentive Plan Implementation Assessment Management Measures (Revised Draft)", and no circumstances prohibiting unlocking under the above regulations have occurred.
After verification, the repurchase and cancellation of restricted stocks complies with the regulations on equity repurchase and cancellation such as the "Measures for the Administration of Equity Incentives for Listed Companies" and the Third Phase Incentive Plan. The repurchase and cancellation of restricted stocks that have been granted but have not yet been released from sale restrictions will not harm the interests of the company and all shareholders. It is agreed that the company intends to repurchase and cancel the restricted shares that have been granted but have not yet been released from sale restrictions to incentive targets who are not eligible for incentives and have not met the conditions for release of sales restrictions.
Among the incentive targets for the first grant of restricted stocks, there are 9 directors and senior executives including Song Lihua, Yao Jianping, Sheng Hai, Zhao Hui, Zhou Yuanyuan, Wang Yongbin, Li Kun, Lu Chunyan, TaWei Chou. Their business performance, work ability and other aspects will be assessed based on their performance assessment results. The individual performance assessment results will be "A". The proportion of individuals who can be lifted from the restricted stock during this period is 100%.
For the first-time incentive recipients and reserved incentive recipients from the Anti-Oncology Division, and the first-time incentive recipients outside the Anti-Oncology Division (excluding directors and senior executives participating in the incentive), the individual performance assessment results are all “A”, and the individual-level unlocking ratio of their sales restriction period is 100%.
In summary, we believe that: According to the company's "Third Incentive Plan", "Third Period Restricted Stock Incentive Plan Implementation Assessment and Management Measures" and other relevant regulations, the conditions for the third unlocking period of shares granted to persons outside the anti-tumor division of the company's third phase incentive plan for the first time have been met, and the third phase incentive plan has achieved The conditions for the first release of the lock-up period for the shares granted to the anti-tumor division of the incentive plan have been met. The conditions for the first release of the lock-up period for the shares granted to the anti-tumor division have been met for the first time. The qualifications of the above-mentioned incentive objects are legal and valid, and meet the qualifications for the release of the lock-up.
We unanimously agreed to submit the above matters to the company's board of directors for review, and agreed that the board of directors would handle the corresponding lifting procedures for incentive objects that meet the conditions for lifting sales restrictions in accordance with the authorization of the company's second extraordinary general meeting of shareholders in 2022 and the relevant provisions of the company's third-phase incentive plan.
(No text below)
Remuneration and Assessment Committee of the Eighth Board of Directors of Anhui Anke Bioengineering (Group) Co., Ltd.
November 21, 2025